A novel ZNF263-SMOX-ROS-TRIB3 signaling axis drives Wnt/β-catenin activation and metastatic progression in colorectal cancer Authors: Longhe Sun, Youlei Zhang, Xianhu Zhang, Jiajie Zhou, Lili Ji, Ruiqi Li, Shuai Zhao, Yayan Fu, Jie Wang, Min Tang, Wei Wang, Chunhua Qian, Qiannan Sun, Daorong Wang Published: 2026 ABSTRACT AbstractSpermine oxidase (SMOX), a key enzyme in polyamine catabolism, has been increasingly linked to tumor progression. However, its regulatory network and biological significance in colorectal cancer (CRC), particularly in metastasis, remain largely undefined. Integrated transcriptomic analyses of CRC peritoneal metastasis samples, GEO datasets, and TCGA cohorts were performed to determine SMOX expression and prognostic value. Functional assays in vitro and xenograft/peritoneal metastasis models in vivo were used to assess the impact of SMOX knockdown or overexpression. Mechanistic studies included pathway enrichment, Western blotting, Co-IP, and ChIP-qPCR. SMOX was consistently upregulated in CRC tissues and cell lines, and high SMOX expression correlated with advanced stage, lymphatic metastasis, and unfavorable prognosis. Functionally, SMOX depletion markedly suppressed CRC cell proliferation, colony formation, migration, and invasion, and impaired tumor growth and peritoneal dissemination in vivo; SMOX overexpression exerted opposite protumorigenic effects. Mechanistically, SMOX elevated intracellular ROS levels, leading to transcriptional upregulation of the pseudokinase TRIB3. TRIB3 interacted with and suppressed GSK-3β activity, consequently stabilizing β-catenin and activating the Wnt/β-catenin pathway. Moreover, we identified ZNF263 as a previously unrecognized transcriptional activator of SMOX; ZNF263 directly bound to the SMOX promoter and drove its overexpression in CRC. Together, these findings delineate a novel “ZNF263–SMOX–ROS–TRIB3–GSK-3β–β-catenin” axis. Our study reveals SMOX as a critical driver of CRC progression and metastasis through ROS-mediated TRIB3 induction and subsequent Wnt/β-catenin activation, under the upstream regulation of ZNF263. This signaling axis provides new mechanistic insights and highlights SMOX/TRIB3 as promising therapeutic targets in CRC.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10495-026-02359-2.Keywords: Colorectal cancer, SMOX, ZNF263, TRIB3, Wnt/β-catenin signaling pathway, Reactive oxygen species, Tumor metastasis Introduction In 2020, there were approximately 19.3 million new cancer cases and nearly 10 million cancer-related deaths worldwide [1]. CRC ranks third in global cancer incidence and second in cancer-related mortality, accounting for about 10% of all cancer cases and deaths. Its incidence shows a steady increase in parallel with higher levels of the Human Development Index [2]. At present, CRC is managed primarily through surgical intervention combined with comprehensive multidisciplinary therapy [3]. However, metastasis, particularly peritoneal dissemination, remains a major clinical challenge: 5–10% of patients present with peritoneal metastases at the time of initial diagnosis, and 4–19% develop peritoneal dissemination during follow-up after curative resection. Moreover, 40–80% of CRC–related deaths are attributed to metastatic disease. Compared with patients with hepatic (median OS: 19.1 months) or pulmonary metastases (median OS: 24.6 months), those with CRC peritoneal metastases (CRPMs) experience significantly poorer survival, with a median overall survival of only 16.3 months [3, 4]. Therefore, elucidating the molecular mechanisms underlying the initiation and progression of metastasis is of paramount importance. Dysregulation of polyamine metabolism is a common feature in many cancers. Polyamines can shape a tumor-promoting microenvironment [5] and modulate antitumor immune responses, contributing to the maintenance of an immunologically “cold” tumor phenotype. Spermine oxidase (SMOX), a key regulatory enzyme in the polyamine metabolic pathway, encodes a flavin adenine dinucleotide (FAD)-dependent oxidase that catalyzes the conversion of spermine to spermidine while generating hydrogen peroxide as a by-product, thereby participating in intracellular polyamine turnover. Notably, SMOX has been reported to be upregulated in various cancers, and its overexpression in tumor tissues serves as an independent prognostic indicator correlated with poor overall survival (p = 0.001) [6]. Sierra et al. demonstrated that SMOX contributes to Helicobacter pylori–induced colitis, DNA damage, and oncogenic signaling, suggesting that targeting SMOX may represent a potential strategy to mitigate H. pylori–associated colorectal carcinogenesis [7]. Furthermore, Hu et al. showed that inhibition of SMOX significantly suppressed tumor growth in hepatocellular carcinoma (HCC) models, potentially through modulation of the PI3K/Wnt/β-catenin signaling pathway, indicating that SMOX may function as an important oncogenic driver in HCC [8]. In our preliminary work, RNA-sequencing was performed on four paired clinical specimens of primary CRC and corresponding peritoneal metastatic lesions. Differential expression analysis revealed that SMOX was significantly upregulated in metastatic foci compared with the primary tumors, suggesting that SMOX may play a critical role in CRC metastasis. To date, however, the involvement and mechanistic basis of SMOX in CRC metastasis, have not been elucidated. Given its potential importance, these findings prompted us to further investigate the functional role of SMOX in CRC cells and its contribution to peritoneal metastatic progression. Materials and methods Cell culture and stable cell line construction The human normal colonic epithelial cell line NCM460 and colorectal cancer cell lines SW480 (ATCC® CCL-228TM), SW620 (ATCC® CCL-227TM), and HCT116 (ATCC® CCL-247TM) were purchased from the American Type Culture Collection (ATCC). All cell lines were regularly tested for mycoplasma contamination using a PCR-based detection kit, and the results were confirmed as negative. The identity of the cell lines was also verified through short tandem repeat (STR) analysis, and the relevant verification reports have been uploaded as supplementary materials. RNA sequencing and bioinformatic analysis Total RNA was extracted from four pairs of primary CRC and matched peritoneal metastatic lesions from patients at Northern Jiangsu People’s Hospital. Supplementary Table 1 summarizes the clinicopathologic features of these four patients, including age, sex, tumor location, TNM stage, differentiation, and treatment history (all patients were treatment-naïve at sample collection). Tumor cellularity exceeded 80% in all samples. Libraries were prepared and sequenced on an Illumina NovaSeq 6000 platform, yielding about 20 GB of clean data per sample with Q30 > 90%. Given the small sample size (n = 4), this discovery cohort was used only for hypothesis generation. All key findings regarding SMOX expression and clinical correlations were subsequently validated in larger independent cohorts, including GEO datasets (GSE74602, n = 30; GSE10950, n = 34; GSE50117, n = 44), TCGA (COAD/READ, n = 623), and our tissue microarray (n = 120). Antibodies and reagents The following antibodies were used: anti-SMOX (Abcam, #ab220188; WB 1:1000), anti-TRIB3 (Proteintech, #13300-1-AP; WB 1:1000, IF 1:50), anti-GSK-3β (CST, #12456; WB 1:1000, Co-IP 1:100), anti-p-GSK-3β (Ser9) (CST, #5558; WB 1:1000, this antibody specifically recognizes GSK-3β only when phosphorylated at Ser9, which is an inhibitory phosphorylation that reduces GSK-3β kinase activity), anti-β-catenin (BD Biosciences, #610154; WB 1:5000), anti-ZNF263 (Sigma-Aldrich, #HPA027620; WB 1:500, ChIP 2 µg), anti-β-actin (Sigma-Aldrich, #A5441; WB 1:10000), and anti-GAPDH (Proteintech, #60004-1-Ig; WB 1:10000). All antibodies were validated by the manufacturers or in prior studies. The Wnt inhibitor aStAx-35R (MedChemExpress, #HY-13948) was used at 5, 10, and 20 µM for 24–48 h based on published data and preliminary dose-response experiments (Fig. 4D). NAC (Sigma-Aldrich, #A9165) was used at 5 mM for 2 h before cell collection, a regimen known to effectively reduce intracellular ROS. SMOX promotes CRC cell proliferation, migration, and invasion via activation of the Wnt/β-Catenin signaling pathway, which can be reversed by the Wnt pathway inhibitor aStAx-35R. A Heatmap of gene clustering in high- and low-SMOX expression groups. B GSEA enrichment plot. C Bubble plot of KEGG pathway enrichment analysis for SMOX-related genes. D Effects of different concentrations of aStAx-35R on cell proliferation and viability measured by CCK-8 assay. E CCK-8 assay showing the effect of SMOX overexpression on SW620 cell proliferation and the partial reversal of this effect by aStAx-35R treatment. F Expression of Wnt pathway proteins including p-GSK-3β(Ser9) (inhibitory phosphorylation) following SMOX knockdown or overexpression. G Genetic validation of aStAx-35R specificity. H Transwell assay assessing the effects of SMOX overexpression on SW620 cell migration and invasion, and the inhibitory effects of aStAx-35R. (I Western blot and quantitative analysis of Wnt pathway protein expression after treatment with different inhibitors and/or SMOX overexpression. Data are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, *p < 0.001 Measurement of intracellular ROS ROS levels were measured using DCFH-DA (Sigma-Aldrich, #D6883). Cells were incubated with 10 µM DCFH-DA in serum-free medium for 30 min at 37 °C in the dark, then washed, trypsinized, and analyzed immediately on a CytoFLEX S flow cytometer (Beckman Coulter). For each sample, 10,000 viable single cells were gated by forward and side scatter, and the mean FITC fluorescence was recorded. Data were processed with FlowJo v10.8.1. Western blot quantification Band intensities were quantified using ImageJ (NIH, version 1.53). Protein levels were normalized to β-actin or GAPDH. For phosphorylated proteins, signals were first normalized to the loading control, then to the corresponding total protein (e.g., p-GSK-3β(Ser9) to total GSK-3β). All data are from at least three independent experiments and are presented as mean ± SD. Animal studies Female BALB/c nude mice (4–6 weeks old) were from the Experimental Animal Center, College of Agriculture, Yangzhou University. Experiments were approved by the Animal Ethics Committee of Northern Jiangsu People’s Hospital and TaiZhou Forth People’s Hospital (No. 2023-EC/TZFH-006) and performed in accordance with institutional guidelines. The maximum permitted tumor burden (2000 mm3) was not exceeded. For the peritoneal metastasis model, 2 × 106 luciferase-labeled HCT116 or SW620 cells (with SMOX modulation) were injected intraperitoneally. After 4–6 weeks, mice were euthanized, and metastatic nodules on the mesentery, intestinal wall, and parietal peritoneum were counted. The lung metastasis model (referenced in Fig. 3) was established by tail vein injection and is described in the Supplementary Methods (Supplementary Fig. 1). Subcutaneous xenograft and lung metastasis models in nude mice. A1 Effect of SMOX knockdown on subcutaneous tumor growth in nude mice (tumor status on day 21). A2: Excised subcutaneous tumors from shCtrl and shSMOX groups. A3) Tumor growth curves (volume vs. time) for shCtrl and shSMOX groups. B1 Effect of SMOX overexpression on subcutaneous tumor growth in nude mice (tumor status on day 21). B2 Excised subcutaneous tumors from Vector and oeSMOX groups. B3 Tumor growth curves (volume vs. time) for Vector and oeSMOX groups. C HCT116 peritoneal metastasis model (shCtrl vs. shSMOX). Yellow dashed lines indicate peritoneal metastatic nodules, with quantitative analysis of nodule number. D SW620 peritoneal metastasis model (Vector vs. oeSMOX). Yellow dashed lines indicate peritoneal metastatic nodules, with quantitative analysis of nodule number. Data are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, *p < 0.001 Statistical analysis Statistical analyses included t-tests, ANOVA, Kaplan–Meier, and Cox regression. For TCGA and GEO data, high and low SMOX expression were separated by the median. For IHC, total score = staining intensity × positive cell percentage (range 0–9), with high expression defined as ≥ 6 and low as < 6 based on score distribution and ROC analysis. Multivariate Cox regression included age, sex, T stage, N stage, M stage, differentiation, and SMOX expression. All in vitro experiments were performed in triplicate biological replicates (n = 3) as indicated in figure legends. Data are presented as mean ± SD. Results SMOX is upregulated in CRC and correlates with poor prognosis RNA-sequencing of four paired CRC primary tumors and matched peritoneal metastases identified 14 consistently dysregulated genes across the three comparisons (Cancer/Control, Metastasis/Control, and Metastasis/Cancer). Among them, SMOX was markedly upregulated in metastatic lesions relative to primary tumors (Fig. 1A–C). Analysis of GEO datasets (GSE74602, GSE10950, GSE50117) confirmed that SMOX expression was significantly higher in CRC tissues than in matched normal tissues (P < 0.001; Fig. 1D). TCGA pan-cancer data further showed broad SMOX overexpression across multiple tumor types, with the most pronounced increase in CRC (COAD and READ) (Fig. 1E–F). Stratification by clinicopathological variables indicated that SMOX upregulation was consistent across lymph node metastasis status, TP53 mutation status, and age subgroups (Fig. 1G). Kaplan–Meier analysis showed that patients with high SMOX expression had significantly poorer overall survival than those with low expression (Fig. 1H). Univariate Cox regression identified SMOX as a risk factor for poor prognosis (HR = 1.49, 95% CI: 1.01–2.22, P = 0.046; Fig. 1I). Consistently, immunohistochemistry on a tissue microarray of 120 paired samples showed a significantly higher proportion of SMOX-high cases in tumors than in adjacent normal tissues (65.0% vs. 12.5%, P < 0.001), with a markedly higher median IHC score in tumors (7 vs. 3, P < 0.001) (Tables 1 and 2; Fig. 1J). High SMOX expression was also associated with advanced T stage, N stage, and distant metastasis (all P < 0.05), and correlated with worse patient outcomes (Table 3; Fig. 1K). Multivariate Cox regression confirmed SMOX as an independent predictor of poor prognosis in CRC (HR = 1.82, 95% CI: 1.15–4.89, P < 0.05). To address the limited number of sequenced cases, we analyzed an independent dataset, GSE225182, which includes 7 peritoneal metastases and 20 primary tumors. Differential expression analysis identified 704 upregulated and 496 downregulated genes (|logFC| > 0.5, P < 0.05), with SMOX significantly upregulated in peritoneal metastases (logFC = 1.09, P = 0.0001) (Fig. 1L). Box plot analysis confirmed that SMOX expression was significantly higher in peritoneal metastases than in primary tumors (P < 0.001) (Fig. 1M). SMOX is upregulated in CRC and predicts poor prognosis. A Venn diagram showing the overlap of differentially expressed genes (DEGs) among Cancer vs. Control, Metastasis vs. Control, and Metastasis vs. Cancer comparisons based on RNA-seq of paired primary and peritoneal metastatic CRC specimens. B Upset plot depicting the intersection size and distribution of shared DEGs across comparison groups. C Differential expression of SMOX between primary tumors and metastatic lesions (left), and between normal and tumor tissues (right). D Validation of SMOX mRNA upregulation in CRC tissues compared with adjacent normal tissues across GEO datasets (GSE74602, GSE10950, and GSE50117). E SMOX expression in paired tumor and normal tissues from TCGA and GTEx datasets. F Pan-cancer dot plot from TCGA showing SMOX expression across 33 tumor types, with the most pronounced increase observed in CRC. G SMOX expression in TCGA-COAD stratified by lymph node status (left), clinical stage (middle), and age (right). H Kaplan–Meier survival curve indicating that high SMOX expression correlates with reduced overall survival in CRC patients. I Univariate Cox regression analysis identifying SMOX as a prognostic risk factor. J Representative immunohistochemical staining of SMOX in CRC tissues and matched adjacent mucosa, demonstrating markedly elevated expression in tumor epithelium. K Multivariate Cox regression analysis confirming SMOX high expression as an independent predictor of poor overall survival. L Volcano plot of differentially expressed genes in the GSE225182 dataset. M SMOX expression levels in primary tumor and peritoneal metastasis samples from the GSE225182 dataset. Data are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, *p < 0.001 Table 1Immunohistochemical scoring criteria and classification methodScoring categoryScoring detailsStaining intensity0 = No staining; 1 = Weak staining;2 = Moderate staining; 3 = Strong stainingPercentage of positive cells0 = 0%; 1 = < 10%; 2 = 10–50%; 3 = > 50%Total scoreStaining intensity score × Positive cell percentage score (range: 0–9)Expression groupingLow expression: Total score < 6; High expression: Total score ≥ 6 Immunohistochemical scoring criteria and classification method 0 = No staining; 1 = Weak staining; 2 = Moderate staining; 3 = Strong staining Table 2SMOX expression levels in CRC tissues and matched adjacent normal tissues (n = 120 pairs)GroupTumor tissueAdjacent normal tissueStatistical valuep-valueHigh expression (≥ 6 points), n(%)78(65.0)15 (12.5)χ2=56.3< 0.001Low expression (< 6 points), n(%)42(35.0%)105(87.5%)Median total IHC, score (range)7(3–9)3(0–6)–< 0.001 SMOX expression levels in CRC tissues and matched adjacent normal tissues (n = 120 pairs) Table 3Clinicopathological features of CRC patients stratified by SMOX expression (n = 120)Clinical featureCategory n SMOX high expression (n = 78)SMOX low expression (n = 42)P valueAge (years)<656342 (53.8%)21 (50.0%)0.712≥ 655736 (46.2%)21 (50.0%)SexMale7246 (59.0%)26 (61.9%)0.843Female4832 (41.0%)16 (38.1%)Tumor diameter<5 cm8252 (66.7%)30 (71.4%)0.402≥ 5 cm3826 (33.3%)12 (28.6%)Tumor differentiationModerate–high8854 (69.2%)34 (81.0%)0.118Poor3224 (30.8%)8 (19.0%)T stageT1~T25226 (33.3%)26 (61.9%)0.003T3~T46852 (66.7%)16 (38.1%)N stageN06231 (39.7%)31 (73.8%)< 0.001N1~N25847 (60.3%)11 (26.2%)MstageM011070 (89.7%)40 (95.2%)0.009M1108 (10.3%)2 (4.8%)Perineural invasionN8658 (74.4%)28 (66.7%)0.278Y3420 (25.6%)14 (33.3%)Vascular invasionN8052 (66.7%)28 (66.7%)0.532Y4026 (33.3%)14 (33.3%) Clinicopathological features of CRC patients stratified by SMOX expression (n = 120) Effects of SMOX on the proliferation, migration, and invasion of CRC cells qRT-PCR analysis revealed that the mRNA level of SMOX was significantly elevated in CRC cell lines (SW480, SW620, and HCT116) compared with normal colonic epithelial cells (NCM460) (Fig. 2A, p < 0.05). Consistently, Western blot results confirmed that SMOX protein expression was markedly increased in these CRC cell lines relative to NCM460 cells (Fig. 2B, p < 0.05). In paired CRC tissues and adjacent normal tissues, 60% of tumors exhibited higher SMOX protein levels than their matched non-tumor samples (Fig. 2C, p < 0.05). Stable SMOX knockdown HCT116 cells (HCT116-shSMOX) and SMOX-overexpressing SW620 cells (SW620-SMOX-OE) were successfully established using lentiviral transduction (Fig. 2D1–D2, 2E1–E2). CCK-8 assays demonstrated that SMOX knockdown significantly suppressed the proliferation of HCT116 cells, whereas SMOX overexpression enhanced the proliferative capacity of SW620 cells (Fig. 2F1–F2). Colony formation assays further supported these findings, as the number and size of colonies were markedly reduced in shSMOX-HCT116 cells, but significantly increased in SMOX-OE SW620 cells (Fig. 2G1–G2). Transwell migration and invasion assays showed that SMOX knockdown impaired the migratory and invasive abilities of HCT116 cells, while SMOX overexpression promoted these phenotypes in SW620 cells (Fig. 2H1–H2). Scratch wound healing assays provided additional validation: shSMOX cells exhibited markedly slower wound closure, whereas SMOX-OE cells displayed accelerated migration and higher wound closure rates (Fig. 2I1–I2). SMOX expression is upregulated in CRC and promotes cell proliferation, migration, and invasion. A qRT-PCR analysis in CRC cell lines (SW480, SW620, and HCT116) and normal colonic epithelial cells (NCM460). B1–B2 Western blot and densitometric analysis of SMOX protein levels in NCM460, SW480, SW620, and HCT116 cells. C1–C2 Western blot and quantification of SMOX expression in ten pairs of CRC (C) and adjacent normal (N) tissues. D1–D2 Validation of SMOX knockdown and overexpression efficiency in colon cancer cells. E1–E2 Western blot confirmation of SMOX knockdown (HCT116) and overexpression (SW620) at the protein level. F1–F2 CCK-8 assay for evaluating the proliferative effects of SMOX knockdown and overexpression in CRC cell lines. G1–G2 Colony formation assay to evaluate the effects of SMOX knockdown and overexpression on the clonogenic capacity of CRC cell lines. H1–H2 Transwell assay to assess the effects of SMOX knockdown and overexpression on the migration and invasion of CRC cell lines. I1–I2 Wound healing assay to evaluate the effects of SMOX knockdown and overexpression on the migratory capacity of CRC cell lines. Data are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, *p < 0.001 In the subcutaneous xenograft model, tumors in the shSMOX group were significantly smaller than those in the control group (187.0 ± 23.25 vs. 484.6 ± 50.55 mm3, p < 0.0001), whereas tumors in the SMOX-OE group were markedly larger than controls (1524.6 ± 329.38 vs. 464.4 ± 115.31 mm3, p < 0.0001) (Fig. 3A–B). In the peritoneal metastasis model, the number of metastatic nodules was significantly reduced in the shSMOX group but substantially increased in the SMOX-OE group (Fig. 3C–D). SMOX regulates CRC cell proliferation and invasion via the Wnt/β-Catenin signaling pathway To investigate the potential signaling pathways mediated by SMOX in CRC, transcriptomic differential expression analysis was performed on high- and low-SMOX expression groups based on the TCGA-COAD dataset. Heatmap analysis revealed that the SMOX-high group exhibited a coordinated activation pattern of genes associated with tumor progression (Fig. 4A). KEGG pathway enrichment analysis identified the Wnt signaling pathway as the most significantly enriched pathway in the SMOX-high group, and GSEA further confirmed global activation of the Wnt/β-Catenin pathway in SMOX-high tumors (NES = 2.07, FDR < 0.001) (Fig. 4B–C).In cellular experiments, SW620 cells were treated with gradient doses of the β-Catenin-specific inhibitor aStAx-35R, which demonstrated a clear dose-dependent inhibition of Wnt signaling (Fig. 4D). Functional rescue assays further showed that SMOX overexpression significantly promoted SW620 cell proliferation, whereas aStAx-35R treatment partially reversed this pro-proliferative effect (Fig. 4E). Western blot analysis revealed that in SMOX-overexpressing cells, total GSK-3β levels remained unchanged, but inhibitory phosphorylation of GSK-3β at Ser9 (p-GSK-3β(Ser9)) was markedly increased, concomitant with upregulation of β-Catenin protein and decreased p-β-Catenin, indicating enhanced β-Catenin stability. Conversely, SMOX knockdown produced the opposite effects (Fig. 4F). To assess the potential off‑target effects of aStAx‑35R, complementary genetic experiments were performed using β-catenin‑specific shRNA (shCTNNB1). Western blot analysis showed that both aStAx‑35R treatment and shCTNNB1 transfection significantly reduced nuclear β‑catenin levels compared with the control group. Importantly, in cells co‑treated with shCTNNB1 and aStAx-35R, no further reduction was observed compared with shCTNNB1 treatment alone (Figure G), indicating no detectable off‑target effects.Transwell assays demonstrated that SMOX overexpression markedly enhanced cell migration and invasion, while aStAx-35R treatment significantly inhibited these effects (Fig. 4H). To further delineate the role of SMOX in Wnt pathway activation, inhibitors targeting different nodes of the pathway were applied. The results showed that aStAx-35R effectively suppressed SMOX-induced β-Catenin accumulation and GSK-3β phosphorylation changes (Fig. 4I), whereas WIF-1 was unable to produce significant inhibition. SMOX regulates TRIB3 expression through ROS, thereby modulating the Wnt/β-Catenin signaling pathway Integrated multi-omics analysis identified a positive correlation between SMOX and several genes in CRC, with TRIB3 showing the strongest association. In TCGA COAD and READ cohorts combined with GTEx data, the Pearson correlation coefficient between SMOX and TRIB3 was 0.60 (FDR < 0.01), placing TRIB3 among the top 20 candidate genes (Table 4). This transcriptional correlation was confirmed across the full cohort (Fig. 5A). Western blotting showed that TRIB3 protein levels were higher in HCT116 cells than in normal colonic epithelial NCM460 cells (p < 0.01) (Fig. 5B). SMOX knockdown reduced TRIB3 protein levels, while SMOX overexpression increased them (Fig. 5C). We next examined apoptosis-related proteins by Western blot. In SW620 cells, oeSMOX lowered cleaved caspase-3 and BAX but raised Bcl-2 (P < 0.05); shTRIB3 had the opposite effect and reversed the oeSMOX-induced changes (Fig. 5D1). In HCT116 cells, shSMOX increased cleaved caspase-3 and BAX and decreased Bcl-2 (P < 0.05), while TRIB3 overexpression had an anti-apoptotic effect and reversed the shSMOX-induced changes (Fig. 5D2). Given the link between SMOX and ROS metabolism, flow cytometry showed that SMOX overexpression increased ROS levels in SW620 cells, an effect reversed by NAC (p < 0.001). Conversely, SMOX knockdown reduced ROS in HCT116 cells, and exogenous ROS partially restored this decrease (p < 0.001) (Fig. 5E). Consistently, NAC treatment blocked the SMOX-induced upregulation of TRIB3 in SW620 cells, while exogenous ROS partially rescued TRIB3 expression in SMOX-knockdown HCT116 cells (Fig. 5F). Immunofluorescence revealed cytoplasmic co-localization of TRIB3 and GSK-3β in both HCT116 and SW620 cells (Fig. 5H). Co-IP further confirmed their physical interaction: when either TRIB3 or GSK-3β was immunoprecipitated, the counterpart protein was detected, with no signal in IgG controls (Fig. 5G1-G2). Table 4Top 20 genes positively correlated with SMOX in colorectal cancer SMOXGene symbolGene IDPCCGene symbolGene IDPCCPSMF1ENSG00000125818.170.64SOX4ENSG00000124766.50.60RBCK1ENSG00000125826.190.63SNRPB2ENSG00000125870.100.59ITPAENSG00000125877.120.61ZCCHC3ENSG00000247315.30.59FAM110AENSG00000125898.120.61PLOD3ENSG00000106397.110.59TRMT6ENSG00000089195.140.61DDRGK1ENSG00000198171.120.58TRIB3ENSG00000101255.100.60NSFL1CENSG00000088833.170.58SNRPBENSG00000125835.170.60ANKEF1ENSG00000132623.150.57CSNK2A1ENSG00000101266.160.60TGFBIENSG00000120708.160.57TTYH3ENSG00000136295.140.60CRNKL1ENSG00000101343.140.57CRLS1ENSG00000088766.110.60EVA1AENSG00000115363.130.57 Top 20 genes positively correlated with SMOX in colorectal cancer SMOX SMOX regulates TRIB3 expression and ROS levels in CRC cells. A Western blot analysis of TRIB3 protein expression in HCT116 cells and corresponding quantification of band intensity. B Scatter plot showing the correlation between SMOX and TRIB3 expression in TCGA CRC patient samples. C Western blot analysis of TRIB3 protein levels in SMOX knockdown (HCT116) and overexpression (SW620) cells. D1–D2 Apoptosis-related protein expression in HCT116 and SW620 cells. E Flow cytometry analysis of intracellular ROS levels in CRC cells affected by SMOX. F TRIB3 protein expression in cells with SMOX overexpression (oe-SMOX), SMOX knockdown (sh-SMOX), and after treatment with the ROS scavenger NAC. H Immunofluorescence showing cytoplasmic co-localization of TRIB3 and GSK-3β in HCT116 and SW620 cells. G1–G2 Co-immunoprecipitation (Co-IP) analysis of the interaction between TRIB3 and GSK-3β. Data are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, *p < 0.001 In rescue experiments, TRIB3 overexpression partially restored p-GSK-3β(Ser9) and β-catenin levels in SMOX-knockdown HCT116 cells (Fig. 6A), while TRIB3 knockdown partially reversed their elevation in SMOX-overexpressing SW620 cells (Fig. 6B). Colony formation assays showed that TRIB3 overexpression rescued the growth defect of SMOX-knockdown HCT116 cells, and TRIB3 knockdown suppressed the enhanced growth of SMOX-overexpressing SW620 cells (Fig. 6C–D). Transwell assays similarly showed that TRIB3 overexpression reversed the migration and invasion defects in SMOX-knockdown HCT116 cells, and TRIB3 knockdown suppressed the enhanced motility of SMOX-overexpressing SW620 cells (Fig. 6E–F). Together, these rescue experiments establish TRIB3 as a key downstream mediator of SMOX-driven malignant phenotypes. TOP/FOP luciferase reporter assays further showed that oeSMOX increased the TOP/FOP ratio in SW620 cells compared with vector control, an effect abolished by co-transfection with siTRIB3; siTRIB3 alone did not affect baseline activity (Fig. 6G). In HCT116 cells, shSMOX reduced the TOP/FOP ratio, which was partially restored by oeTRIB3 (Fig. 6H). Rescue experiments. A–B Western blot analysis of GSK-3β, p-GSK-3β(Ser9) (inhibitory phosphorylation), β-catenin, and p-β-catenin protein levels. C Effect of SMOX overexpression and TRIB3 knockdown on colony formation ability in SW620 cells. D Effect of SMOX knockdown and TRIB3 overexpression on colony formation ability in HCT116 cells. E Effect of SMOX knockdown and TRIB3 overexpression on migration and invasion capacity in HCT116 cells. F Effect of SMOX overexpression and TRIB3 knockdown on migration and invasion capacity in SW620 cells. G–H TOP/FOP luciferase reporter assay. Data are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, *p < 0.001 ZNF263 functions as a transcription factor regulating SMOX expression To investigate the upstream transcriptional mechanisms underlying SMOX overexpression in CRC, we first analyzed the SMOX promoter region (2 kb upstream of the transcription start site) using the JASPAR and PROMO transcription factor prediction databases. Among the candidate transcription factors, ZNF263 exhibited the highest predicted binding confidence within the SMOX promoter region (Fig. 7A). Correlation analysis based on the combined TCGA-COAD/READ and GTEx datasets further revealed a significant positive correlation between ZNF263 and SMOX mRNA levels (R = 0.30, p < 0.001), suggesting that ZNF263 may act as a potential transcriptional activator of SMOX (Fig. 7B). Western blot analysis showed that ZNF263 protein expression was markedly elevated in CRC cell lines compared with normal colonic epithelial cells, with the highest expression detected in HCT116 cells (Fig. 7C). ZNF263 knockdown and overexpression constructs were successfully established (Fig. 7D–E). In HCT116 cells, siRNA-mediated knockdown of ZNF263 significantly reduced SMOX protein levels (Fig. 7F), whereas exogenous overexpression of ZNF263 in SW480 cells increased SMOX expression (Fig. 7G). To determine whether ZNF263 directly binds to the SMOX promoter, chromatin immunoprecipitation (ChIP)–qPCR assays were performed in HCT116 cells. The results confirmed that SMOX promoter sequences were significantly enriched in ZNF263-immunoprecipitated chromatin compared with IgG controls, indicating direct transcriptional regulation (Fig. 7H). ZNF263 directly regulates SMOX transcription in CRC.A Predicted transcription factor binding sites within the SMOX promoter region (− 2000 bp) based on JASPAR and PROMO databases. B Correlation analysis of SMOX and ZNF263 expression in TCGA-COAD/READ and GTEx datasets (Spearman test). C Western blot analysis of ZNF263 protein expression in CRC cell lines. D ZNF263 protein expression following knockdown in HCT116 cells. (E) ZNF263 protein expression following overexpression in SW480 cells. F1–F2 SMOX protein levels in HCT116 cells after siRNA-mediated ZNF263 knockdown. G1–G2 SMOX protein expression in SW480 cells after ZNF263 overexpression (oeZNF263). H1–H2 ChIP assays showing binding of ZNF263 to the SMOX promoter region. Data are presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, *p < 0.001 Discussion In tis study, by integrating multi-omics data analysis, in vitro functional assays, in vivo animal models, and mechanistic investigations, we systematically elucidated the oncogenic role of SMOX in CRC, as well as its upstream regulation and downstream signaling axis. Our findings not only confirm SMOX as a critical prognostic biomarker, but, more importantly, for the first time reveal a complete signaling cascade driven by ZNF263 transcription, which activates the Wnt/β-catenin pathway via the SMOX/ROS/TRIB3 axis. This provides a novel mechanistic framework for understanding the invasive and metastatic behavior of CRC. First, across multiple independent cohorts—including our own RNA-seq data, GEO, and TCGA datasets—we consistently observed that SMOX is significantly upregulated in CRC tissues and peritoneal metastases. To address the limited sample size of the discovery RNA-seq cohort (n = 4), we further validated SMOX expression in an independent dataset GSE225182, which includes 7 peritoneal metastasis and 20 primary tumor samples. Consistent with our initial findings, SMOX was significantly upregulated in peritoneal metastasis compared with primary tumors (logFC = 1.09, P = 0.0001). Its expression level is closely associated with advanced TNM stage, lymph node metastasis, and poor patient prognosis, a finding consistent with the report by Kim et al.6, strongly suggesting a pivotal role for SMOX in the clinical progression of CRC. Subsequent gain- and loss-of-function experiments convincingly demonstrated that SMOX is a key driver of malignant phenotypes in CRC: it markedly enhances cancer cell proliferation, colony formation, migration, and invasion, and directly promotes tumor growth and peritoneal metastasis in mouse models. These results not only systematically validate the previously reported oncogenic role of SMOX in other cancers, such as hepatocellular carcinoma [8], but also further establish its critical function in the metastatic process of CRC in vivo. (Fig. 8) Schematic diagram of the Wnt/β-catenin signaling pathway mechanism At the mechanistic level, a central finding of this study is the identification of SMOX as a novel upstream activator of the Wnt/β-catenin signaling pathway. The Wnt/β-catenin pathway is a key regulator of embryonic development, tissue homeostasis, and cell fate determination, and its aberrant activation is closely associated with the initiation and progression of various cancers, particularly CRC [9]. The canonical Wnt pathway primarily relies on the regulation of β-catenin stability: in the resting state, a “destruction complex” composed of APC, AXIN1, and GSK-3β phosphorylates β-catenin, targeting it for proteasomal degradation. Upon binding of Wnt ligands (e.g., WNT3A, WNT1) to the Frizzled receptor and LRP5/6 co-receptor at the cell membrane, the destruction complex is inhibited, leading to cytoplasmic accumulation of β-catenin, its nuclear translocation, and subsequent binding to TCF/LEF transcription factors to drive the expression of downstream target genes such as MYC, CCND1, and AXIN210 (Fig. 9). It is important to note that phosphorylation of GSK-3β at Ser9 is an inhibitory modification that reduces its kinase activity. Therefore, increased p-GSK-3β(Ser9) leads to decreased β-catenin phosphorylation and degradation, ultimately resulting in β-catenin stabilization and nuclear accumulation. This sequence is fully consistent with the β-catenin protein levels observed in our study (e.g., increased total and nuclear β-catenin upon SMOX overexpression). Schematic illustration of the “ZNF263-SMOX-ROS-TRIB3-Wnt/β-catenin” signaling axis in CRC Although aberrant Wnt signaling is a cornerstone of colorectal tumorigenesis [10], our study highlights that, beyond classical APC/CTNNB1 mutations [11], the metabolic enzyme SMOX represents an alternative and significant mechanism for pathway activation. Preliminary enrichment analysis using TCGA datasets (GSEA) suggested this association, which was then confirmed by molecular experiments: SMOX overexpression selectively increased GSK-3β phosphorylation at Ser9 and stabilized β-catenin protein levels, effects that could be reversed by the specific inhibitor aStAx-35R. Notably, inhibition of Wnt signaling at the ligand level using WIF-1 did not completely abrogate the activation effect of SMOX, indicating that SMOX acts downstream of the ligand-receptor interaction, likely directly on the β-catenin destruction complex itself. We used β‑catenin‑specific shRNA (shCTNNB1) to test for off‑target effects of aStAx‑35R. Both aStAx‑35R treatment and shCTNNB1 transfection reduced nuclear β‑catenin levels. Co‑treatment with shCTNNB1 and aStAx‑35R did not further reduce nuclear β‑catenin compared with shCTNNB1 alone (Fig. 4G), confirming that aStAx‑35R acts specifically through the β‑catenin pathway. TOP/FOP luciferase reporter assays showed that SMOX overexpression increased the TOP/FOP ratio, while SMOX knockdown decreased it. These effects depended on TRIB3: TRIB3 knockdown blocked the SMOX‑induced increase, and TRIB3 overexpression rescued the decrease caused by SMOX knockdown (Fig. 6G‑H). Thus, SMOX activates Wnt/β‑catenin transcriptional activity via TRIB3, complementing our protein stability data. This finding expands our understanding of the regulatory network of the Wnt pathway and provides a mechanistic explanation for CRCs exhibiting pathway activation in the absence of canonical Wnt pathway mutations. How, then, does SMOX regulate the β-catenin destruction complex? Our subsequent investigations focused on reactive oxygen species (ROS) and their downstream effector, TRIB3. TRIB3 is reported to be highly expressed in solid tumors such as hepatocellular carcinoma [12], lung cancer [13], and CRC [14], and is considered a potential oncogene. SMOX, as a spermidine oxidase, is known to generate ROS as a core function [15]. Our data confirmed a positive correlation between SMOX expression levels and intracellular ROS concentration. More importantly, ROS was identified as a critical mediator linking SMOX to TRIB3 expression. ROS scavenging significantly attenuated the SMOX-mediated upregulation of TRIB3, whereas exogenous ROS supplementation partially rescued the decrease in TRIB3 expression caused by SMOX knockdown. TRIB3, a multifunctional pseudokinase, has been reported to promote tumor progression in various cancers by modulating multiple signaling pathways [16]. In this study, Co-immunoprecipitation (Co-IP) and immunofluorescence experiments provided the first evidence in CRC models that TRIB3 directly interacts with GSK-3β. We propose that TRIB3 binds to and inhibits GSK-3β activity, thereby impairing the phosphorylation and degradation capacity of the destruction complex toward β-catenin, ultimately leading to β-catenin stabilization and nuclear translocation. We manipulated TRIB3 expression in cells with altered SMOX levels. TRIB3 knockdown reduced SMOX‑induced increase in inhibitory p-GSK-3β(Ser9) and suppressed proliferation, migration, and invasion, while TRIB3 overexpression partially restored the effects of SMOX knockdown (Fig. 6A‑J). Thus, TRIB3 acts as a key downstream mediator of SMOX. We also tested whether this axis affects apoptosis. SMOX overexpression lowered cleaved caspase‑3 and BAX and raised Bcl‑2, indicating reduced apoptosis; SMOX knockdown had the opposite effect. These changes were TRIB3‑dependent: TRIB3 knockdown reversed the anti‑apoptotic effect of SMOX overexpression, and TRIB3 overexpression rescued the pro‑apoptotic effect of SMOX knockdown (Fig. 5D1–D2). Together, these findings show that the SMOX‑ROS‑TRIB3 axis promotes proliferation and metastasis while suppressing apoptosis, contributing to tumor progression through multiple mechanisms. This finding complements Hua et al. [16], who demonstrated that TRIB3 can form a transcriptional complex with β-catenin/TCF4, collectively illustrating a comprehensive role of TRIB3 in the Wnt pathway as a “signal amplifier”: it stabilizes β-catenin in the cytoplasm while enhancing its transcriptional activity in the nucleus. Finally, to address the fundamental question of why SMOX is overexpressed in CRC, we extended our investigation to the level of transcriptional regulation. Through bioinformatic prediction and expression correlation analyses, ZNF263 was identified as a potential upstream transcription factor of SMOX. Experimental validation demonstrated that ZNF263 is also highly expressed in CRC cells and can directly bind to the promoter region of SMOX, as confirmed by ChIP-qPCR. Functionally, ZNF263 knockdown downregulated SMOX expression, whereas ZNF263 overexpression upregulated it. These findings elegantly explain the mechanism underlying SMOX transcriptional upregulation and establish ZNF263 as the initiating hub of the entire signaling cascade. This is consistent with the oncogenic role of ZNF263 reported in other cancers, such as cholangiocarcinoma (CCA) [17], hypothalamic hamartoma (HH) [18], and glioblastoma [19], but our study is the first to link it to the key polyamine metabolic enzyme SMOX, forming a complete oncogenic axis from transcriptional regulation to metabolic reprogramming and subsequent signal transduction. Of course, this study has several limitations. For instance, the precise structural basis by which TRIB3 inhibits GSK-3β activity remains unresolved; the universality of the SMOX/ZNF263 axis across heterogeneous CRC subtypes, such as CMS classifications, requires validation in larger cohorts; and the interaction between this signaling axis and the tumor microenvironment, including immune cell infiltration, warrants further investigation. Although we have shown Wnt transcriptional activation by TOP/FOP assays, the structural basis of how TRIB3 inhibits GSK-3β kinase activity remains unclear and will require kinase activity assays and co‑immunoprecipitation with deletion mutants. Second, while the SMOX‑ROS‑TRIB3 axis modulates apoptosis in CRC cells, its crosstalk with other apoptotic pathways (e.g., p53, PI3K/AKT) needs further investigation. Third, whether the SMOX/ZNF263 axis operates across different CRC subtypes (e.g., CMS classifications) requires validation in larger cohorts. Fourth, the interaction between this axis and the tumor microenvironment, including immune cell infiltration, remains to be explored. Fifth, clinical validation of SMOX and TRIB3 as therapeutic targets in CRC metastasis will require larger prospective cohorts. In summary, we delineate a previously uncharacterized ZNF263–SMOX–ROS–TRIB3–Wnt/β-catenin signaling axis in CRC (Fig. 8). Each component of this axis represents a potential therapeutic target. Developing small-molecule inhibitors against SMOX enzymatic activity or its downstream effector TRIB3, or combining ZNF263 inhibitors with existing Wnt pathway inhibitors such as aStAx-35R, may provide a novel precision medicine strategy to combat CRC, particularly in cases of refractory metastasis. Conclusion SMOX is consistently upregulated in CRC and correlates with advanced stage and poor prognosis. Functional assays confirm that SMOX drives cell proliferation, migration, invasion, and in vivo tumor growth and metastasis. Mechanistically, we uncover a ZNF263–SMOX–ROS–TRIB3–Wnt/β‑catenin axis: ZNF263 directly activates SMOX transcription; SMOX elevates ROS, which in turn upregulates TRIB3; TRIB3 binds GSK‑3β, leading to β‑catenin stabilization and Wnt pathway activation. Rescue experiments establish TRIB3 as a key downstream mediator of SMOX. TOP/FOP assays confirm that this axis activates Wnt transcriptional activity, and apoptosis assays show it also suppresses cell death. Together, these findings reveal a novel mechanism driving CRC progression and identify SMOX and TRIB3 as potential therapeutic targets. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file 1 (PDF 7039 kb) Supplementary file 2 (PDF 9101 kb) Supplementary file 3 (PDF 18738 kb) Supplementary file 4 (PDF 7993 kb) Supplementary file 5 (PDF 6697 kb) Supplementary file 6 (DOCX 14 kb) Author contributions Longhe Sun: Conceptualization, Methodology, Investigation, Writing—Original Draft. Youlei Zhang: Methodology, Validation, Formal analysis, Investigation, Writing—Original Draft. Xianhu Zhang: Software, Validation, Data Curation, Visualization. Jiajie Zhou: Investigation, Resources.Lili Ji: Investigation, Resources. Ruiqi Li: Investigation, Resources. Shuai Zhao: Formal analysis, Data Curation. Yayan Fu: Supervision, Project administration. Jie Wang: Supervision, Project administration. Min Tang: Writing—Review & Editing. Wei Wang: Writing—Review & Editing. Chunhua Qian: Funding acquisition. Qiannan Sun: Funding acquisition. Daorong Wang: Conceptualization, Resources, Writing—Review & Editing, Supervision, Funding acquisition. Funding Taizhou Science and Technology Support Program (Social Development,2024). Joint University-Local Collaborative Innovation Research Project of Jiangsu Vocational College of Medicine and Yancheng Municipal Health Commission (2024). Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.The datasets generated and supporting the findings of this study, including all original experimental data (e.g., raw Western blot images, Transwell and wound healing assay images, primary animal experiment data, and vector maps), are available for peer review upon request. The data are curated and can be accessed via: https://pan.baidu.com/s/18OlQsuaQxftrK39rFpiuVA. The access password will be provided to the editorial office and reviewers upon request to ensure confidentiality during the peer review process. Upon acceptance, these data will be deposited in a public, permanent repository (e.g., Figshare or Zenodo) and the corresponding accession number/DOI will be provided in the final publication. Declarations Conflict of interest The authors declare that they have no conflict of interest. Ethical Approval The ethical committee of Northern Jiangsu People’s Hospital and TaiZhou Forth People’s Hospital approved this study (Ethical Number: 2023-EC/TZFH-006). Consent for publication Not applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Youlei Zhang, Xianhu Zhang and Lili Ji have contributed equally to this work. Contributor Information Longhe Sun, Email: 15295214701@163.com. Daorong Wang, Email: wdaorong666@sina.com. References Associated Data Supplementary Materials Supplementary file 1 (PDF 7039 kb) Supplementary file 2 (PDF 9101 kb) Supplementary file 3 (PDF 18738 kb) Supplementary file 4 (PDF 7993 kb) Supplementary file 5 (PDF 6697 kb) Supplementary file 6 (DOCX 14 kb) Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.The datasets generated and supporting the findings of this study, including all original experimental data (e.g., raw Western blot images, Transwell and wound healing assay images, primary animal experiment data, and vector maps), are available for peer review upon request. The data are curated and can be accessed via: https://pan.baidu.com/s/18OlQsuaQxftrK39rFpiuVA. The access password will be provided to the editorial office and reviewers upon request to ensure confidentiality during the peer review process. Upon acceptance, these data will be deposited in a public, permanent repository (e.g., Figshare or Zenodo) and the corresponding accession number/DOI will be provided in the final publication.